Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials

Summary of the Second Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II)

1993 • 28,274 citations

Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)

2001 • 24,089 citations

Guidelines for the Use of Antiretroviral Agents in HIV-Infected Adults and Adolescents

1998 • 4,297 citations

UPDATE ON DRUG RESISTANCE MUTATIONS IN HIV-1

2001 • 1,694 citations

Treatment for Adult HIV Infection

2006 • 1,052 citations

Treatment for Adult HIV Infection

2004 • 749 citations

TMC114, a Novel Human Immunodeficiency Virus Type 1 Protease Inhibitor Active against Protease Inhibitor-Resistant Viruses, Including a Broad Range of Clinical Isolates

2005 • 358 citations

Incidence and Risk Factors for Immune Reconstitution Inflammatory Syndrome in an Ethnically Diverse HIV Type 1-Infected Cohort

2006 • 347 citations

Durable efficacy of tipranavir-ritonavir in combination with an optimised background regimen of antiretroviral drugs for treatment-experienced HIV-1-infected patients at 48 weeks in the Randomized Evaluation of Strategic Intervention in multi-drug reSistant patients with Tipranavir (RESIST) studies: an analysis of combined data from two randomised open-label trials

2006 • 326 citations

Atazanavir plus ritonavir or saquinavir, and lopinavir/ritonavir in patients experiencing multiple virological failures

2005 • 250 citations

Allocation of Patients to Treatment in Clinical Trials

1979 • 237 citations

Update of the Drug Resistance Mutations in HIV-1: 2005.

2005 • 195 citations

Efficacy and safety of TMC114/ritonavir in treatment-experienced HIV patients: 24-week results of POWER 1

2007 • 178 citations

Durable Efficacy of Enfuvirtide Over 48 Weeks in Heavily Treatment-Experienced HIV-1-Infected Patients in the T-20 Versus Optimized Background Regimen Only 1 and 2 Clinical Trials

2005 • 150 citations

Week 24 efficacy and safety of TMC114/ritonavir in treatment-experienced HIV patients

2007 • 112 citations

Update of the drug resistance mutations in HIV-1: 2004.

2004 • 81 citations

Risk of AIDS and death at given HIV-RNA and CD4 cell count, in relation to specific antiretroviral drugs in the regimen.

2005 • 61 citations